The Bull Case For Tempus AI (TEM) Could Change Following Profit Return, Outlook Hike And Personalis Deal - Learn Why

• In the past quarter, Tempus AI, Inc. reported second-quarter 2026 revenue of US$382.49 million, turning a US$42.84 million loss a year ago into a US$5.64 million net profit and lifting basic earnings per share from a US$0.25 loss to US$0.03.
• The company also raised its full-year 2026 revenue outlook to US$1.60 billion at the midpoint, signaling management’s increased confidence following this earnings beat and the announced acquisition of cancer genomics firm Personalis.
• We’ll now examine how this raised 2026 revenue guidance and return to quarterly profitability reshape Tempus AI’s existing investment narrative.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Tempus AI Investment Narrative Recap

To own Tempus AI, you need to believe its genomics and AI data platforms can convert growing clinical and biopharma adoption into sustainable profitability. The return to a small quarterly profit and higher 2026 revenue guidance strengthen the near term catalyst around improving margins, but the biggest risk remains whether reimbursement and client budgets will support continued growth in higher value tests and data contracts.

The most relevant update is Tempus AI’s raised full year 2026 revenue outlook to about US$1.60 billion, which builds on its Q2 revenue beat and first quarterly profit in this period. This updated guidance sits alongside the planned Personalis acquisition and an expanding product portfolio, and together they frame how quickly Tempus AI might move from intermittent profitability to a more consistent earnings profile.

Yet beneath the stronger guidance, a key risk investors should be aware of is whether payors will fully support reimbursement for Tempus’s newer AI driven diagnostics and...

Read the full narrative on Tempus AI (it's free!)

Tempus AI's narrative projects $2.4 billion revenue and $374.7 million earnings by 2029. This requires 20.8% yearly revenue growth and about a $678 million earnings increase from -$302.9 million today.

Uncover how Tempus AI's forecasts yield a $66.53 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most optimistic analysts were assuming Tempus could reach about US$2.7 billion in revenue and positive earnings by 2029, so if you think progress on FDA backed assays and AI reimbursement will be faster than the consensus fears, you may see the story very differently.

Explore 7 other fair value estimates on Tempus AI - why the stock might be worth just $65.90!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com